Follow-up of a major linkage peak on chromosome 1 reveals suggestive QTLs associated with essential hypertension: GenNet study

European Journal of Human Genetics

Volumn 17, Issue 12, 2009, Pages 1650-1657

  Ehret, Georg B ^a,b   O'Connor, Ashley A ^a   Weder, Alan ^c   Cooper, Richard S ^d   Chakravarti, Aravinda ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5; GLYCOPROTEIN; GLYCOPROTEIN A33; PRORENIN; PROTEIN CD247; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CHROMOSOME 1Q; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ESSENTIAL HYPERTENSION; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AMERICAN NATIVE CONTINENTAL ANCESTRY GROUP; CHROMOSOMES, HUMAN, PAIR 1; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION; LINKAGE (GENETICS); MALE; MIDDLE AGED; PHENOTYPE; QUALITY CONTROL; QUANTITATIVE TRAIT LOCI; YOUNG ADULT;

EID: 70450227480     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2009.94     Document Type: Article

References (23)

1. Wilson PW: Established risk factors and coronaryTartery disease: the Framingham Study. Am J Hypertens 1994; 7: 7S-12S.
2. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ: Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. Lancet 2006; 367: 1747-1757.
3. Staessen JA, Fagard R, Thijs L et al: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350: 757-764.
4. Multi-center genetic study of hypertension: The Family Blood Pressure Program (FBPP). Hypertension 2002; 39: 3-9.
5. Thiel BA, Chakravarti A, Cooper RS et al: A genome-wide linkage analysis investigating the determinants of blood pressure in whites and African Americans. Am J Hypertens 2003; 16: 151-153.
6. Chang YP, Liu X, Kim JD et al: Multiple genes for essential-hypertension susceptibility on chromosome 1q. Am J Hum Genet 2007; 80: 253-264.
7. Hardenbol P, Baner J, Jain M et al: Multiplexed genotyping with sequence-tagged molecular inversion probes. Nat Biotechnol 2003; 21: 673-678.
8. Hardenbol P, Yu F, Belmont J et al: Highly multiplexed molecular inversion probe genotyping: Over 10,000 targeted SNPs genotyped in a single tube assay. Genome Res 2005; 15: 269-275.
9. Moorhead M, Hardenbol P, Siddiqui F et al: Optimal genotype determination in highly multiplexed SNP data. Eur J Hum Genet 2006; 14: 207-215.
10. BarreAt JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21 263-265.
11. PArcell S, Neale B, Todd-Brown K et al: PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
12. Abecasis GR, Cherny SS, Cookson WO, Cardon LR: Merlin - rapid analysis of dense genetic maps using sparse gene flow trees. Nat Genet 2002; 30: 97-101.
13. Lange C, Silverman EK, Xu X, Weiss ST, Laird NM: A multivariate family-based association test using generalized estimating equations: FBAT-GEE. Biostatistics 2003; 4: 195-206.
14. Tobin MD, Sheehan NA, Scurrah KJ, Burton PR: Adjusting for treatment effects in studies of quantitative traits: Antihypertensive therapy and systolic blood pressure. Stat Med 2005; 24: 2911-2935.
15. Frazer KA, Ballinger DG, Cox DR et al: A second generation human haplotype map of over 3.1 million SNPs. Nature 2007; 449: 851-861.
16. Franklin SS, Larson MG, Khan SA et al: Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001; 103: 1245-1249.
17. JenseT C, Herold P, Brunner HR: Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov 2008; 7: 399-410.
18. Moore N, Dicker P, O'Brien JK et al: Renin gene polymorphisms and haplotypes, blood pressure, and responses to renin-angiotensin system inhibition. Hypertension 2007; 50: 340-347.
19. Martinelli I, Bucciarelli P, Margaglione M, De Stefano V, Castaman G, Mannucci PM: The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. Br J Haematol 2000; 111: 1223-1229.
20. Makris TK, Krespi PG, Hatzizacharias AN et al: Resistance to activated protein C and FV leiden mutation in patients with a history of acute myocardial infarction or primary hypertension. Am J Hypertens 2000; 13: 61-65.
21. Heath JK, White SJ, Johnstone CN et al: The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. Proc Natl Acad Sci USA 1997; 94: 469-474.
22. Weissman AM, Baniyash M, Hou D, Samelson LE, Burgess WH, Klausner RD: Molecular cloning of the zeta chain of the T cell antigen receptor. Science 1988; 239: 1018-1021.
23. Ehret GB, Morrison AC, O'Connor AA et al: Replication of the Wellcome Trust genome-wide association study of essential hypertension: The Family Blood Pressure Program. Eur J Hum Genet 2008; 16: 1507-1511.